Brägelmann, Johannes http://orcid.org/0000-0002-1306-2169
Lorenz, Carina
Borchmann, Sven
Nishii, Kazuya
Wegner, Julia http://orcid.org/0000-0001-8103-8040
Meder, Lydia
Ostendorp, Jenny
Ast, David F.
Heimsoeth, Alena
Nakasuka, Takamasa
Hirabae, Atsuko
Okawa, Sachi
Dammert, Marcel A. http://orcid.org/0000-0003-4269-7822
Plenker, Dennis http://orcid.org/0000-0003-3895-4064
Klein, Sebastian
Lohneis, Philipp http://orcid.org/0000-0002-4797-0018
Gu, Jianing
Godfrey, Laura K.
Forster, Jan
Trajkovic-Arsic, Marija
Zillinger, Thomas http://orcid.org/0000-0002-0866-4835
Haarmann, Mareike
Quaas, Alexander
Lennartz, Stefanie
Schmiel, Marcel
D’Rozario, Joshua http://orcid.org/0000-0002-3380-4801
Thomas, Emily S.
Li, Henry http://orcid.org/0000-0002-4673-1234
Schmitt, Clemens A. http://orcid.org/0000-0002-4731-2226
George, Julie http://orcid.org/0000-0002-4272-3683
Thomas, Roman K.
von Karstedt, Silvia http://orcid.org/0000-0002-7816-5919
Hartmann, Gunther http://orcid.org/0000-0003-1021-2018
Büttner, Reinhard http://orcid.org/0000-0001-8806-4786
Ullrich, Roland T.
Siveke, Jens T. http://orcid.org/0000-0002-8772-4778
Ohashi, Kadoaki
Schlee, Martin http://orcid.org/0000-0003-3671-7639
Sos, Martin L. http://orcid.org/0000-0002-2868-100X
Funding for this research was provided by:
Deutsche Krebshilfe (70113307, 70113129, 701125509, 70113009, 70113835, 70112888)
Else Kröner-Fresenius-Stiftung (2018_EKMS, 2016-Kolleg-19, 2016-Kolleg-19)
Deutsche Forschungsgemeinschaft (PL 894/1-1, SFB1399, SCHL1930/1-2, TRR237, SFB670, CRC1399, SI1549/3-1, SCHL1930/1-2, TRR237, CRC1399)
Bundesministerium für Bildung und Forschung (01ZX1901A, 01ZX1901A, 01ZX1901A)
Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen (EFRE-0800397, 1411ng005)
MEXT | Japan Society for the Promotion of Science (19K08625)
Article History
Received: 25 November 2020
Accepted: 23 August 2021
First Online: 17 September 2021
Competing interests
: M.L.S. is a founder and shareholder of PearlRiver Bio (now part of Centessa Pharmaceuticals) and received consulting honoraria from PearlRiver Bio. M.L.S. receives research funding from PearlRiver Bio and Novartis. R.B. is an employee of Targos Molecular Pathology. H.L. is an employee of CrownBiosciences. G.H. is co‐founder of Rigontec GmbH. M.S. is listed as inventor on a patent application covering RIG-I activating structures. R.K.T. is founder of PearlRiver Bio (now part of Centessa Pharmaceuticals), founder of NEO New Oncology (now part of Siemens Healthcare), consulting honoraria from PearlRiver Bio and NEO New Oncology. K.O. received research funding from Boehringer Ingelheim, Novartis, AstraZeneca, Eli Lilly, and Daiichi-Sankyo outside the submitted work. K.O. reports honoraria from AstraZeneca, MSD and Chugai pharmaceutical outside the submitted work. The other authors declare no competing interests.